Related Experiment Video
Updated: Jul 19, 2026
Viral Nanoparticles for In vivo Tumor Imaging
Published on: November 16, 2012
[Killing effect of VP3 on human nasopharyngeal carcinoma cell line CNE-2 cells]
Jing Xu1, Yuan-zheng Qiu, Yao-yun Tang
1Department of Otolaryngology, Xiangya Hospital, Central South University, Changsha 410008, China.
Objective:
To investigate the killing effects of VP(3) on nasopharyngeal carcinoma cell line CNE-2.
Methods:
Plasmid expression vector pcDNA3.1(-) CMV.VP(3)-His was constructed and identified by Kpn I/EcoR I endonuclease analysis, and then sequenced to verify successful insertion in the sense direction of VP(3) gene. pcDNA3.1(-) CMV.VP(3)-His and pcDNA3.1(-)-His expression plasmid was transiently transfected into nasopharyngeal carcinoma cell line CNE-2 . VP(3) protein expression was detected by Western blotting. MTT assay was used to determine the killing effects of VP(3) gene on nasopharyngeal carcinoma cell line CNE-2.
Results:
Endonuclease analysis and sequencing confirmed the recombinant plasmid contained the complete VP(3) CDS sequence. Western blotting detected a 14.03 kD protein expression from the transfected cells, which was the expecting band of VP(3) gene. The growth of CNE-2 cells that expressed VP(3) gene was inhibited,while the growth of CNE-2 cells that did not express VP(3) gene was not inhibited.
Conclusion:
VP(3) gene can kill nasopharyngeal carcinoma cell CNE-2.
Insights
The VP(3) gene effectively inhibits the growth of nasopharyngeal carcinoma (NPC) cells. This study confirms VP(3) has significant killing effects on the CNE-2 NPC cell line.
Area of Science:
- Molecular Biology
- Cancer Research
- Virology
Context:
- Nasopharyngeal carcinoma (NPC) is a significant health concern, particularly in certain geographic regions.
- Understanding the molecular mechanisms underlying NPC proliferation is crucial for developing targeted therapies.
- The VP(3) gene's role in cancer cell biology warrants investigation.
Purpose:
- To evaluate the cytotoxic effects of the VP(3) gene on the CNE-2 nasopharyngeal carcinoma cell line.
- To construct and validate a plasmid expression vector for VP(3) gene delivery.
- To confirm VP(3) protein expression in transfected NPC cells.
Summary:
- A recombinant plasmid, pcDNA3.1(-) CMV.VP(3)-His, was successfully constructed and verified.
- Transient transfection of the VP(3) gene into CNE-2 cells led to detectable VP(3) protein expression.
- MTT assays demonstrated significant inhibition of CNE-2 cell growth upon VP(3) gene expression.
Impact:
- The VP(3) gene exhibits potent anti-cancer activity against nasopharyngeal carcinoma cells.
- This finding suggests VP(3) as a potential therapeutic candidate for NPC treatment.
- Further research into VP(3) gene therapy for NPC is warranted.
